Syngene reports stable Q3FY20 numbers
Syngene reports stable Q3FY20 numbers

Syngene reports stable Q3FY20 numbers

Amir Shaikh Article rating: 5.0

Syngene International reported its third quarter result of FY20 on Wednesday after the market hours. The company’s Q3FY20 revenue was at Rs 539 crore, representing an increase of 11 per cent from the corresponding quarter last year.

GE T&D shines after bagging project worth Rs 173 crore
GE T&D shines after bagging project worth Rs 173 crore

GE T&D shines after bagging project worth Rs 173 crore

Apurva Joshi Article rating: 4.6

GE T&D India Limited has been awarded Supervisory Control and Data Acquisition (SCADA) and Advanced Distribution Management Solution (ADMS) project by the Jammu & Kashmir Power Development Department (JKPDD) for the distribution operations in the cities of Jammu and Srinagar.

Closing Bell: Sensex closes above 271 points, Nifty up by 73 points
Closing Bell: Sensex closes above 271 points, Nifty up by 73 points

Closing Bell: Sensex closes above 271 points, Nifty up by 73 points

Avalokita Pandey Article rating: 3.5

After ending the day in red on Wednesday, the Sensex closed today’s trading session in green, which is, above 200 points and Nifty too ended in green. While the Sensex closed at 41,386.40 levels, up by 0.66 per cent, Nifty closed at 12,179.90 levels, up by 0.60 per cent.

KEC International bags multiple orders worth Rs 1,255 crore
KEC International bags multiple orders worth Rs 1,255 crore

KEC International bags multiple orders worth Rs 1,255 crore

Apurva Joshi Article rating: 3.8

KEC International Limited has bagged new orders worth Rs 1,255 crore, across various businesses. KEC International, which is a part of the RPG Group, has a presence in the verticals of power transmission and distribution, railways, civil, solar, smart infrastructure and cables.

Alembic Pharmaceuticals receive USFDA nod for Fenofibrate tablets
Alembic Pharmaceuticals receive USFDA nod for Fenofibrate tablets

Alembic Pharmaceuticals receive USFDA nod for Fenofibrate tablets

DSIJ Intelligence Article rating: 5.0

Alembic Pharmaceuticals announced that it has received final approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate tablets USP, 54 mg and 160 mg. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Tricor tablets, 54 mg and 160 mg of AbbVie Inc.

Myths regarding fixed income investments
Myths regarding fixed income investments

Myths regarding fixed income investments

DSIJ Intelligence Article rating: 5.0

Fixed income investment has been one of the most preferred investments traditionally. However, there are certain myths with respect to fixed income investments that need to be busted. Let’s find out what are they!

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 5.0

The market opened in the green on 23rd January, overall volumes in futures & options currently stand at 2.36 crore contracts with a turnover of Rs. 16,74,537.87 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.7

The market opened in the green on 23rd January, overall volumes in futures & options currently stand at 2.36 crore contracts with a turnover of Rs. 16,74,537.87 crore.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

DSIJ Intelligence Article rating: 4.0

The market opened in the green on 23rd January. The previous day witnessed the Sensex going down by 208.43 points to end at 41,115.38 and the Nifty was down by 62.95 points to close at 12,106.90.

Retail investors form 90 per cent of domestic MF investors
Retail investors form 90 per cent of domestic MF investors

Retail investors form 90 per cent of domestic MF investors

DSIJ Intelligence Article rating: 5.0

The Asset under Management (AUM) of domestic mutual fund industry has more than doubled in the last few years. It is the increased participation of retail investors that has helped to record such a growth.

RSS
First30953096309730983100310231033104Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR